Objective:

To compare the effectiveness of initiating buprenorphine-naloxone versus extended-release naltrexone specifically after opioid withdrawal management.

Approach:

• Study Design: An observational comparative effectiveness study using a target trial emulation framework with deidentified data from the Massachusetts Public Health Data Warehouse.
• Eligibility Criteria: Included individuals 18 years or older discharged from voluntary medically managed opioid withdrawal (MMOW) between January 1, 2014, and December 31, 2018, excluding those with certain psychiatric diagnoses and prior methadone use.
• Treatment Strategies: Participants were assigned to either XR naltrexone or buprenorphine-naloxone based on pharmacy and medical claims within 28 days of MMOW discharge.
• Outcome Measures: All-cause mortality and nonfatal opioid overdose were assessed within 24 weeks of MMOW discharge using death certificate data and hospital records.

Key Findings:

• Prior studies suggest methadone and buprenorphine-naloxone may reduce fatal and nonfatal opioid overdose compared to XR naltrexone.
• The X:BOT trial reported no significant differences in overdose rates between buprenorphine-naloxone and XR naltrexone groups based on its primary analysis.
• A reanalysis indicated a higher overdose risk in the XR naltrexone group, but this finding was sensitive to the analytic approach used.

Interpretation:

The study aims to evaluate mortality and overdose outcomes using a larger observational dataset.

Limitations:

• The study is observational and may be subject to biases inherent in non-randomized data, such as selection bias and confounding.
• Powering RCTs to examine infrequent outcomes like mortality or overdose may not be feasible.

Conclusion:

The study utilizes a target trial emulation framework to compare the effectiveness of two medications for opioid use disorder in a real-world setting.